Zenas BioPharma (ZBIO) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Zenas BioPharma (ZBIO) overview

Zenas BioPharma (ZBIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 10.0m and operating profit of USD -383m; the year-end share price was 36.31 USD and market capitalisation was USD 1,978m. Zenas BioPharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Zenas BioPharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 242mFY 2025
Share price36.31 USDFY 2025 year end
RevenueUSD 10.0mFY 2025
Operating profitUSD -383mFY 2025
Net earningsUSD -378mFY 2025
Market capitalisationUSD 1,978mFY 2025 year end

About Zenas BioPharma

Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases. Its lead candidate, obexelimab, is a monoclonal antibody designed to inhibit B-cell activity. The company is evaluating obexelimab in clinical trials for IgG4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus, serving patients with these conditions through potential therapeutic treatments.

Generate the Zenas BioPharma report

Zenas BioPharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Zenas BioPharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Zenas BioPharma

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.